These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 20664589)
21. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related]
22. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*. Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563 [TBL] [Abstract][Full Text] [Related]
24. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. Kim EH; Andriole GL; Crawford ED; Sjoberg DD; Assel M; Vickers AJ; Lilja H J Urol; 2017 Apr; 197(4):1041-1047. PubMed ID: 27810449 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522 [TBL] [Abstract][Full Text] [Related]
26. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H; Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509 [TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149 [TBL] [Abstract][Full Text] [Related]
28. Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy. Hill OT; Mason TJ; Schwartz SW; Foulis PR BMC Urol; 2013 Jan; 13():6. PubMed ID: 23356551 [TBL] [Abstract][Full Text] [Related]
29. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7. Scott E; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M Urol Oncol; 2017 Mar; 35(3):120. PubMed ID: 28215847 [TBL] [Abstract][Full Text] [Related]
30. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645 [TBL] [Abstract][Full Text] [Related]
31. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Beemsterboer PM; Kranse R; de Koning HJ; Habbema JD; Schröder FH Int J Cancer; 1999 Aug; 84(4):437-41. PubMed ID: 10404100 [TBL] [Abstract][Full Text] [Related]
32. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892 [TBL] [Abstract][Full Text] [Related]
33. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899 [TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Roobol MJ; Kranse R; de Koning HJ; Schröder FH Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478 [TBL] [Abstract][Full Text] [Related]
35. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort. Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781 [TBL] [Abstract][Full Text] [Related]
36. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Vertosick EA; Zappala S; Punnen S; Hugosson J; Boorjian SA; Haese A; Carroll P; Cooperberg M; Bjartell A; Lilja H; Vickers AJ Urology; 2021 Nov; 157():102-106. PubMed ID: 34450175 [TBL] [Abstract][Full Text] [Related]
37. PSA density improves prediction of prostate cancer. Verma A; St Onge J; Dhillon K; Chorneyko A Can J Urol; 2014 Jun; 21(3):7312-21. PubMed ID: 24978363 [TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481 [TBL] [Abstract][Full Text] [Related]
39. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Gosselaar C; Roobol MJ; van den Bergh RC; Wolters T; Schröder FH Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045 [TBL] [Abstract][Full Text] [Related]
40. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination. Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]